S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Twitter executive responsible for content safety resigns after Elon Musk criticism
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Twitter executive responsible for content safety resigns after Elon Musk criticism
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Twitter executive responsible for content safety resigns after Elon Musk criticism
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Twitter executive responsible for content safety resigns after Elon Musk criticism
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
NASDAQ:PRAX

Praxis Precision Medicines (PRAX) Price Target & Analyst Ratings

$1.01
+0.13 (+14.77%)
(As of 06/2/2023 ET)
Compare
Today's Range
$0.92
$1.04
50-Day Range
$0.80
$1.12
52-Week Range
$0.79
$8.75
Volume
1.69 million shs
Average Volume
622,663 shs
Market Capitalization
$62.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

Praxis Precision Medicines Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 6 Analyst Ratings

Consensus Analyst Price Target

$10.25
914.85% Upside
High Prediction$18.00
Average Prediction$10.25
Low Prediction$4.00
TypeCurrent
6/4/22 to 6/4/23
1 Month Ago
5/5/22 to 5/5/23
3 Months Ago
3/6/22 to 3/6/23
1 Year Ago
6/4/21 to 6/4/22
Consensus Rating
Moderate Buy
Hold
Hold
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
3 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$10.25$10.50$10.50$36.67
Predicted Upside914.85% Upside480.91% Upside484.43% Upside113.10% Upside
Get Praxis Precision Medicines Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter.


PRAX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PRAX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Praxis Precision Medicines Stock vs. The Competition

TypePraxis Precision MedicinesMedical CompaniesS&P 500
Consensus Rating Score
2.50
2.66
2.49
Consensus RatingModerate BuyBuyHold
Predicted Upside914.85% Upside1,263.19% Upside209.76% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/2/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy
5/12/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$16.00 ➝ $15.00+1,301.86%
3/3/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Minter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
6/7/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$65.00 ➝ $18.00+878.26%
6/7/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$4.00+112.77%
6/6/2022Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Chico
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$4.00+61.94%
(Data available from 6/4/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












PRAX Price Target - Frequently Asked Questions

What is Praxis Precision Medicines's consensus rating and price target?

According to the issued ratings of 6 analysts in the last year, the consensus rating for Praxis Precision Medicines stock is Hold based on the current 3 hold ratings and 3 buy ratings for PRAX. The average twelve-month price prediction for Praxis Precision Medicines is $10.25 with a high price target of $18.00 and a low price target of $4.00. Learn more on PRAX's analyst rating history.

Do Wall Street analysts like Praxis Precision Medicines more than its competitors?

Analysts like Praxis Precision Medicines less than other Medical companies. The consensus rating for Praxis Precision Medicines is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how PRAX compares to other companies.

Does Praxis Precision Medicines's stock price have much upside?

According to analysts, Praxis Precision Medicines's stock has a predicted upside of 465.91% based on their 12-month price targets.

What analysts cover Praxis Precision Medicines?

Praxis Precision Medicines has been rated by HC Wainwright, and Jefferies Financial Group in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:PRAX) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -